Analysts Conflicted on These Healthcare Names: Bristol-Myers Squibb (BMY) and Envista Holdings (NVST)
Stifel Maintains Envista Holdings(NVST.US) With Buy Rating, Maintains Target Price $24
Envista Holdings Price Target Raised to $17.00/Share From $16.00 by Piper Sandler
Envista Upgraded to Market Perform by Leerink, Management Cited
Evercore Maintains Envista Holdings(NVST.US) With Buy Rating, Raises Target Price to $26
Stifel Maintains Envista Holdings(NVST.US) With Buy Rating, Raises Target Price to $24
A Quick Look at Today's Ratings for Envista Holdings(NVST.US), With a Forecast Between $19 to $26
Envista Holdings Is Maintained at Neutral by Baird
Leerink Partners Upgrades Envista Holdings to Market Perform, Raises Price Target to $23
Envista Holdings Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Humana (HUM)
BofA Securities Maintains Envista Holdings(NVST.US) With Buy Rating
Bank of America Securities Keeps Their Buy Rating on Envista Holdings (NVST)
Envista Holdings Analyst Ratings
Stifel Maintains Buy on Envista Holdings, Raises Price Target to $21
Envista Holdings Initiated at Equal-Weight by Wells Fargo
Wells Fargo Initiates Envista Holdings(NVST.US) With Hold Rating, Announces Target Price $20
Envista Holdings Is Maintained at Outperform by Evercore ISI Group
Envista Holdings Analyst Ratings
Evercore Maintains Envista Holdings(NVST.US) With Buy Rating, Raises Target Price to $23